Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Join us at TCT2024 in Washington DC where Shockwave Medical and our clinical partners will bring to life long-awaited innovations that move the field of IVL FORWARD! Visit the Shockwave booth and go hands-on with the highly anticipated Shockwave Javelin catheter and our latest peripheral catheter, Shockwave E8. Join colleagues at the Shockwave Symposium on Tuesday, October 29 where a panel of experts will show how you can veto challenging calcium by backing our latest calcium contenders.
Topics: Coronary IVL, IVL Technology, Shockwave C2, Coronary Conferences
Q2 is in the books and it was full of electrifying news, big accomplishments and new beginnings. Of course, a major milestone was the acquisition of Shockwave Medical by Johnson & Johnson MedTech. This new journey is off to a great start and we’re excited about how this partnership will help us expand access to our life-changing technologies across the globe.
Updates from the Reducer team for our international physician partners include publishing new data that show positive news for patients suffering from Refractory Angina.* Additionally, our Size for Success training about sizing up for the best Peripheral IVL results is also gaining traction and was featured in several publications. Read the latest PulsePoint Newsletter to learn more about important milestones from Q2!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD, Reducer
There’s no better way to start a new year than building positive momentum. Between great developments on coronary reimbursement to positive real-world data for Reducer, 2024 is off to a shock-worthy start.
Another highlight was the continuous enrollment of patients in our EMPOWER CAD Study — the first prospective clinical study in the interventional space completely dedicated to female patients. Our team also created new resources about optimal sizing for Peripheral IVL, as well as put the final touches on our new manufacturing facility in Costa Rica. Read more about our strong start and get excited about what’s to come in the latest edition of the PulsePoint Newsletter.
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD, Reducer
Get your wetsuits ready because Shockwave's SCAI 2024 lineup will cause some serious waves in Long Beach. Take a look at the hot topics Shockwave has in store for you this year including:
Topics: Coronary IVL, IVL Technology, Shockwave C2, Coronary Conferences
What a fantastic finish! From launching the new 120-pulse Shockwave C2+ catheter in the U.S. to establishing a new Category I CPT® Add-on Code for coronary IVL, Q4 was filled with wave-making moments and positive momentum.
One highlight was the release of sex-specific outcomes data for both coronary and peripheral IVL from the DISRUPT PAD III, DISRUPT CAD III and CAD IV studies. Additionally, the DISRUPT PAD III study provided important data supporting the practice of sizing up by 10% for peripheral IVL. Look back at a few of our most noteworthy Q4 accomplishments and get excited about what’s coming in 2024 in the latest issue of the PulsePoint Newsletter.
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD, Reducer
From the first U.S. Shockwave C2+ case to the unveiling of the 2023 TopShock finalists, this past quarter had a lively pulse all its own. In other news, we’re very excited to share the impressive results from the 2-year DISRUPT CAD III study of IVL for Treatment of Severely Calcified Coronary Arteries.
For our international customers, there was an excellent poster session presented during ESC Congress that featured three presentations on our Coronary Sinus Reducer*. We also launched a series of real-world application videos from VAM 2023 that highlight Shockwave L6 and the benefits of using it to tackle calcium in large vessels. Dive head first into the latest PulsePoint Newsletter to learn more about the big waves made in Q3!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD, Reducer
Attending TCT in San Francisco in a few weeks? Come see how we're making waves by the Bay through a lineup of real-world evidence:
Topics: Coronary IVL, IVL Technology, Shockwave C2, Coronary Conferences
Kalzium ist nicht nur oberflächlich ... manchmal muss man in die Tiefe!
Topics: Coronary IVL, IVL Technology, Shockwave C2, Coronary Conferences
Over the past three months, Shockwave continued to ride a big wave of momentum with new product launches, inclusions in new journal articles, a pulse-racing presence at EuroPCR and more. The launch of Shockwave L6 Peripheral IVL Catheter in the U.S. came with physician-led case reviews, Q&As and more valuable content that demonstrate the big impact it can make in large peripheral vessels. We also turned up the heat at EuroPCR in Paris, where we showcased live cases, hosted an engaging symposium and participated in PCR TV interviews - all while focusing heavily on the European launch of our Shockwave C2+ Coronary IVL Catheter, which includes 50% more pulses than the original Shockwave C2. Dive right in and catch the wave of excitement in the latest issue of the PulsePoint newsletter!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD
EuroPCR 2023 was a real blast for Shockwave Medical! Three sponsored sessions, two featured live cases,one interview on PCR TV andmany, many invaluable conversations at our booth. Thank you to all of you who attended for making this our best EuroPCR so far!
Topics: Coronary IVL, IVL Technology, Shockwave C2, Coronary Conferences
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
